Sanofi SA (SNY)
49.36
+2.75
(+5.90%)
USD |
NASDAQ |
Apr 25, 16:00
48.67
-0.69
(-1.40%)
After-Hours: 05:31
Sanofi Free Cash Flow (Quarterly)
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | 3.037B |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | 10.22B |
| March 31, 2021 | |
| June 30, 2020 | 3.573B |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 2.627B |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 1.134B |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | 1.714B |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 1.590B |
| March 31, 2016 | |
| December 31, 2015 |
| Date | Value |
|---|---|
| September 30, 2015 | |
| June 30, 2015 | 2.911B |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 2.602B |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | 1.694B |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | 4.547B |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 | |
| June 30, 2011 | 4.428B |
| March 31, 2011 | |
| December 31, 2010 | |
| September 30, 2010 | |
| June 30, 2010 | 4.565B |
| March 31, 2010 | |
| December 31, 2009 | |
| September 30, 2009 |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
2.627B
Minimum
Jun 2019
10.22B
Maximum
Jun 2021
4.864B
Average
3.305B
Median
Free Cash Flow (Quarterly) Benchmarks
| AstraZeneca PLC | 1.434B |
| GSK PLC | 2.958B |
| Novo Nordisk A/S | -1.065B |
| Regeneron Pharmaceuticals Inc | 776.20M |
| Inhibrx Inc | -60.26M |